Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
Relapsed Ovarian Cancer
DRUG: Fluzoparib|DRUG: Apatinib
Progression Free Survival(PFS), To determine the efficacy by progression free survival (PFS) of the maintenance treatment in previous PARP inhibitor treated platinum-sensitive relapsed ovarian cancer patients according to RECIST v1.1 criteria (Investigator determined)., Up to 2 years
Objective Response Rate (ORR), Up to 2 years|Disease Control Rate (DCR）, Up to 2 years|Overall survival (OS）, Up to 2 years|Adverse Events (AEs), Assese the safety and tolerability of Fluzoparib combined with apatinib maintenance in platinum sensitive relapsed ovarian cancer patients by record the number of participants with of AEs and SAEs, and the proportion of patients with AEs and SAEs, etc., From the first drug administration to within 30 days for the last treatment dose
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .